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Abstract NPM1 mutations, the most frequent molecular
alterations in acute myeloid leukemia (AML), have become
important for risk stratification and treatment decisions for
patients with normal karyotype AML. Rapid screening for
NPM1 mutations should be available shortly after diagnosis.
Several methods for detecting NPM1 mutations have been
described, most of which are technically challenging and
require additional laboratory equipment. We developed and
validated an assay that allows specific, rapid, and simple
screening for NPM1 mutations. FAST PCR spanning exons
8 to 12 of the NPM1 gene was performed on 284 diagnostic
AML samples. PCR products were visualized on a 2 %
agarose E-gel and verified by direct sequencing. The FAST
PCR screening method showed a specificity and sensitivity
of 100 %, i.e., all mutated cases were detected, and none of
negative cases carried mutations. The limit of detection was
at 5–10 % of mutant alleles. We conclude that the FAST
PCR assay is a highly specific, rapid (less than 2 h), and
sensitive screening method for the detection of NPM1 muta-
tions. Moreover, this method is inexpensive and can easily
be integrated in the routine molecular diagnostic work-up of
established risk factors in AML using standard laboratory
equipment.
Keywords NPM1 . Acute myeloid leukemia . Mutation
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Introduction
In acute myeloid leukemia (AML), an increasing number of
genetic alterations have been described to be involved in the
pathogenesis of the disease, and to determine the phenotype
and the impact of the treatment [1]. As a consequence, the
identification of molecular alterations by cytogenetic and/or
molecular analysis is of great importance for risk stratification
and treatment decisions. Molecular analyses are particularly
important in AML patients with a normal karyotype who
constitute about half of all AML cases [2].
NPM1 mutations represent the most frequent alterations in
AML, occurring in approximately one third of adult patients
with AML, and are associated with a normal karyotype in
85 % of cases [3]. In the 2008 World Health Organization
(WHO) classification, AML with mutated nucleophosmin
(NPM1) has been defined as a separate provisional entity,
and there is increasing evidence that NPM1 mutations repre-
sent founder genetic events in AML. Various studies have
demonstrated the favorable prognostic impact of NPM1muta-
tions especially in the absence of a FLT3 ITD [4–8].
On the molecular level,NPM1mutations are insertions that
cluster within exon 11 and 12 of the NPM1 gene. The inser-
tions typically consist of 1 or 2 tetranucleotides at nucleotides
956 to 971 (reference sequence NM_002520) corresponding
to nucleotides c.860 through c.875 (HGVS nomenclature) [9].
The most prevalent mutation is the 960insTCTG (type A
mutation) that is present in approximately 80 % of cases. Rare
cases of non-tetrameric insertions and deletions/insertions
have been described as well as single cases of 8-bp insertions
in exon 11 leading to a truncated protein [10, 11]. All muta-
tions in exon 12 lead to a frame-shift and an elongated protein
E. Oppliger Leibundgut :N. A. Porret :M. Bienz Muggli :
G. M. Baerlocher
Laboratory of Molecular Diagnostics, Department of Hematology,
University Hospital Bern and University of Bern,
Freiburgstrasse 4,
CH-3010 Bern, Switzerland
E. Oppliger Leibundgut (*) :H. Baumgartner :M. Dahlhaus :
G. M. Baerlocher
Experimental Hematology, Department of Clinical Research,
University of Bern,
CH-3010 Bern, Switzerland
e-mail: elisabeth.oppliger@insel.ch
Ann Hematol (2013) 92:173–177
DOI 10.1007/s00277-012-1617-9
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
12
59
7 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
with loss of the nucleolar localization domain and/or gain of a
nuclear export signal resulting in an accumulation of the
protein in the cytoplasm. A variety of molecular methods for
detecting NPM1 mutations have been described, including
PCR amplification and direct sequencing, high-resolution
fragment analysis based on a fluorescence-labeled forward
primer (Genescan), melting curve analysis on the LightCycler
system, denaturing high-performance liquid chromatography
(DHPLC), and LNA-mediated PCR clamping [12]. These
methods are technically challenging and require well-trained
personnel and additional laboratory equipment that might not
be available in many molecular routine laboratories. Hence,
since the detection of NPM1 mutations at diagnosis is impor-
tant for risk stratification and treatment decision, molecular
laboratories should be able to perform the initial analysis using
their standard laboratory equipment.We therefore developed a
rapid and simple screening assay based on FAST PCR ampli-
fication and standardized agarose gel electrophoresis.
Materials and methods
Patient samples
We validated our assay on 284 diagnostic samples from
adult patients with AML referred to our laboratory, includ-
ing 158 NPM1-mutated (NPM1-mt) samples and a series of
126 in-house NPM1-wild-type (NPM1-wt) samples. Patients
were diagnosed according to the WHO criteria at the Univer-
sity Hospitals of Bern, Basel, and Zürich and the District
Hospitals of Lucerne, Bellinzona, St. Gallen, Thun, and Aarau.
All patients were enrolled in the multicenter prospective trials
of the HOVON/SAKK Study Group (HOVON AML proto-
cols 42, 43, 81, 92, 102, 103) or treated according to the
HOVON/SAKK protocols after informed consent according
to the declaration of Helsinki. Patient characteristics are given
in Table 1. All samples of bone marrow or peripheral blood
were collected at diagnosis.
Table 1 Patient characteristics
NPM1 mutated (n0158) NPM1 wild-type (n0126) p value
no. no.
Age at diagnosis, years, median (range) 58 (17–87) 56 (20–78) 0.116
Sex F/M 86/72 49/77 0.009
WBC,×109/L, median (range) 145 26.3 (0.2–346.6) 126 6.6 (0.7–183.9) < 0.0005
% Blasts in blood, median (range) 132 40.5 (0–98) 103 39.5 (0.5–95) 0.807
FAB classification 135 122
M0 3 ( 2.2) 24 (19.7) < 0.0005
M1 30 (22.2) 28 (23.0) 0.889
M2 39 (28.9) 29 (23.8) 0.353
M4 25 (18.5) 19 (15.6) 0.531
M5 34 (25.2) 4 (3.3) < 0.0005
M6 1 ( 0.7) 6 (4.9) 0.056
M7 0 3 (2.6) 0.106
RAEB-2 3 ( 2.2) 7 ( 5.7) 0.200
Secondary AML following MDS 0 2 ( 1.6) 0.224
Cytogenetics 131 126
Normal karyotype, no. (%) 106 (80.9) 61 (48.4) < 0.0005
Favorablea, no. (%) 0 10 (7.9) 0.001
Intermediate-IIa, no. (%) 18 (13.7) 14 (11.1) 0.523
Adversea, no. (%) 7 (5.3) 41 (32.5) 0.001
Molecular genetics
AML1-ETO, no. (%) 150 0 118 7 (5.9) 0.003
CBFb-MYH11, no. (%) 149 0 118 3 (2.5) 0.085
CEBPA mutations, no. (%) 23 2 ( 8.7) 43 5 (11.6) 0.655
FLT3 ITD, no. (%) 147 62 (42.2) 121 6 (5.0) < 0.0005
EVI1 overexpression, no. (%) 14 0 21 1 (4.4) 1.00
a Cytogenetic groups according to ELN classification (13). Favorable: t(8;21)(q22;q22); inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). Intermediate-II:
t(9;11)(p22;q23); cytogenetic abnormalities not classified as favorable or adverse. Adverse: inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); t(6;9)(p23;q34);
t(v;11)(v;q23); -5 or del(5q); -7; abnl(17p); complex karyotype
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Mutational analysis
Total RNAwas extracted from Ficoll-separated mononuclear
cells using the QIAmp RNA Blood Mini Kit (Qiagen,
Hombrechtikon, Switzerland) and reverse transcribed by the
Superscript II system (Invitrogen, Lucerne, Switzerland). For
mutational analysis, a primer pair was designed to amplify
exons 8 to 12 of the NPM1 gene (NPM663F 5′-GCGCCAGT-
GAAGAAATCTATAC-3′ and NPM1109R 5′-GGACAA-
CATTTATCAAACACGG-3′) yielding a 446-bp product.
Two microliters of cDNA were amplified in a volume of
20 μl containing 0.5 μM of each primer and 10 μl of 2×
GeneAmp Fast PCR Master Mix (Applied Biosystems,
Rotkreuz, Switzerland) on a 9800 or Veriti Fast Thermal
Cycler (Applied Biosystems). Reaction conditions consisted
of an initial denaturation step at 94 °C for 10 s followed by
35 cycles at 94 °C for 0 s, 60 °C for 5 s, and 72 °C for 20 s and
a final elongation step at 72 °C for 30 s. PCR products
were run for 40 min on a 2 % agarose E-gel
(Invitrogen) where a double band indicates a mutation
and a single band represents the wild-type sequence. All
PCR products were verified by direct sequencing in
both directions using BigDye Terminator Mix version
3 (Applied Biosystems, Rotkreuz, Switzerland) on an
ABI3130xl automated sequencer. PCR products yielding
a small smear above the wild-type band were sequenced with
primers NPM793F (5 ′ -AAAACTCCTAAAACAC
CAAAAGGACC-3′), NPM883F (5′-AAAGTGGAAGC
CAAATTCATCAA-3′), NPM845R (5′-CACCTTTTTCTA
TACTTGTTGCATTT-3′), and NPM964R (5′-TATTTTCT
TAAAGAGACTTCCTCCA-3′).
With FAST PCR, thermal cycling reactions that normally
take over an hour and a half can take as little as 25 min. The
FAST PCR technique is performed on designated FAST
PCR thermal cyclers and optimized reagents must be used.
Alternatively, our PCR protocol was also run by standard
conditions on an ABI 9700 Thermal Cycler (Applied
Biosystems) using Roche Taq polymerase (Roche, Rotkreuz,
Switzerland) and buffer. Reaction conditions consisted
of denaturation at 95 °C for 5 min, 35 cycles at 95 °C
for 30 s, 60 °C for 30 s, and 72 °C for 45 s and a final
elongation at 72 °C for 5 min. Results were consistent, but
PCR products were somewhat fainter probably due to a lower
PCR efficiency.
Statistical analysis
Statistical analyses were performed on SPSS 17.0 for
Windows (SPSS Inc., Chicago, Illinois). The nonpara-
metric Wilcoxon–Mann–Whitney test was used for con-
tinuous data and the χ2 or Fisher exact (whenever an
expected value was <5) test for categorical data to
compare demographic, laboratory and molecular parameters
between the patient groups. A p value of <0.05 was
considered statistically significant.
Results
Of 284 AML samples included in the study, 158 were
NPM1 mutated and 126 were wild-type as determined
by FAST PCR screening. Mutated PCR products inva-
riably showed two distinct bands on agarose gel elec-
trophoresis, probably based on heteroduplex formation
(Fig. 1). All mutated and wild-type PCR products were
directly sequenced in both directions, and the results
were 100 % concordant with the screening method.
Mutations included 151 typical 4-bp insertions and 6
uncommon mutations in exon 12 (Table 2). In addition,
a 19-bp deletion was detected in exon 9 outside the
commonly mutated region leading to a frame-shift and a
premature stop codon.
1    2     3     4     5     6     7     8     9    10 Fig. 1 After FAST PCR, PCRproducts are visualized on a
2 % agarose E-gel, where a
double band indicates a muta-
tion and a single band represents
the wildtype sequence. Lanes 1
100 bp ladder, 2, 3 and 7 patient
samples with wild-type NPM1,
4–6 patient samples with mutat-
ed NPM1, 8 positive control cell
line OCI-AML3, 9 wild-type
control cell line HL60, 10 no
template control
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In 2 samples with mutated and 10 samples with wild-
type NPM1, a novel 3-bp in frame-deletion in exon
8 (748delTCA) was identified resulting in a loss of
serin 218 (p.Ser218del). We detected this sequence
variation in samples of patients with other hematological
malignancies and healthy donors at variable proportions
(CML, 0/18; ALL, 3/18; CLL, 5/12; healthy donors, 14/15)
suggesting to represent a common polymorphism. The
frequency and potential relevance of this sequence variation is
currently under investigation in our laboratory.
Specificity and sensitivity of FAST PCR screening
The specificity and diagnostic sensitivity of the FAST PCR
screening method were 100 %, i.e., all positive samples
carried mutations and none of the 126 negative cases
were mutated (positive predictive value of 1.00 and
negative predictive value of 1.00). The limit of detection
(LOD) of the assay as assessed by serial dilution experiments
of the cell line OCI-AML3 in the negative cell line HL60 was
5–10 % mutated alleles.
NPM1 mutations and biological and morphological features
The incidence of NPM1 mutations was higher in women
(NPM1-mt, women, n086 (54 %); men n072; NPM1-wt,
women, n049 (39 %), men n077, p00.009). The median
ages of patients with and without NPM1 mutations were 58
and 56 years, respectively. Patients with NPM1mutations had
significantly higher median white blood cell counts than
patients without NPM1 mutations (26.3×109/L versus
6.6×109/L; p<0.0005). No difference was observed with
regard to the peripheral blast count (NPM1-mt, median,
40.5; NPM1-wt, median, 39.5). NPM1 mutations were
predominantly found in the French–American–British
(FAB) subgroups M1, M2, M4, and M5, and were less
frequent in M0, M6, and M7. When compared to the
NPM1-wt group, NPM1 mutations were significantly
less frequent in FAB M0 and more frequent in FAB
M5 (FAB M0, 2.2 % versus 19.7 %; p<0.0005; FAB
M5, 25.2 % versus 3.3 %; p<0.0005).These data confirm the
known features of many reports reviewed in [3].
NPM1 mutations and cytogenetic and molecular features
Cytogenetic data were available for 257 of the 284 patients
with AML. In accordance with results from other studies,
NPM1 mutations were significantly associated with a nor-
mal karyotype (NPM1-mt, 80.9 %; NPM1-wt, 48.4 %; p<
0.0005) [3]. Patients with an aberrant karyotype were clas-
sified in cytogenetic risk groups according to the recom-
mendations of the European LeukemiaNet [13]. We found
significantly less patients with NPM1 mutations in the fa-
vorable and adverse cytogenetic subgroups compared to
patients without NPM1 mutations (favorable, 0 versus
7.9 %; p00.001; adverse, 5.3 % versus 32.5 %; p00.001);
13.7 % and 11.1 % of patients with and without NPM1
mutations carried chromosomal aberrations of type
Table 2 NPM1 mutations detected by FAST PCR screening
Type of mutation Exon Nucleotide sequence Protein Number % of 
mutated
21epyt-dliW CAAGATC----TCTG--------GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLWQWRKSL 126  
21A CAAGATC----TCTGTCTG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCLAVEEVSLRK 117 75
21B CAAGATC----TCTGCATG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCMAVEEVSLRK 16 10
21D CAAGATC----TCTGCCTG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCLAVEEVSLRK 9 6
21G CAAGATC----TCTGTTTG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCLAVEEVSLRK 3 2
213DD/VI CAAGATC----TCTGCAGA----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCRAVEEVSLRK 1 <1
215DD CAAGATC----TCTGTCAG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCQAVEEVSLRK 1 <1
217D CAAGATCATGTTCTG--------GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDHVLAVEEVSLRK 1 <1
21mG CAAGATC----TCTGCAGG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCRAVEEVSLRK 1 <1
21J CAAGATC----TCTGTATG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCMAVEEVSLRK 1 <1
21mN CAAGATC----TCTGCCAG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCQAVEEVSLRK 1 <1
21GTTYsni069 CAAGATC----TCTGYTTG----GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLCLAVEEVSLRK 1 <1
21GGGTTATsni069 CAAGATC----TCTGTATTGGG-GCAG----T----GGAGGAAGTCTCTTT MTDQEAIQDLWYWAVEEVSLRK 1 <1
21AAAAsni469 CAAGATC----TCTG--------GCAGAAAAT----GGAGGAAGTCTCTTT MTDQEAIQDLWQKMEEVSLRK 1 <1
965-970delinsCCCTCTCTCG 12 CAAGATC----TCTG--------GCAG----TCCCTCTCTCGAGTCTCTTT MTDQEAIQDLWQSLSRVSLRK 1 <1
966-970delinsTTTTAGTCC 12 CAAGATC----TCTG--------GCAG----TGTTTTAGTCCAGTCTCTTT MTDQEAIQDLWQCFSPVSLRK 1 <1
933_936delTGAC  
960insTCTGTCTG 
12 CAAGATC----TCTGTCTGTCTGGCAG----T----GGAGGAAGTCTCTTT MTKRLFKISVCLAVEEVSLRK 1 <1
AAACCCTTCTCTTGGTG---------------------GTAAAAACGA9led768_948 KAKMVVLFPKWKPNSSIMstop 1 <1
Genbank RefSeq Accession number NM_002520
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intermediate II. Analysis of concomitant molecular aberra-
tions confirmed the significant known association of NPM1
mutations and FLT3 ITD (42.2 % versus 5 %; p<0.0005).
No AML1-ETO and CBFb-MYH11 fusions were found in
the NPM1-mutated group. The frequencies of CEBPA muta-
tions and EVI1 overexpression were not different in patients
with and without NPM1 mutations.
Discussion
Given the favorable prognostic value of the NPM1+/
FLT3 ITD− genotype and the resulting therapeutic con-
sequences, a rapid and simple method to assess the
presence of NPM1 mutations is required. In this report,
we show that FAST PCR and subsequent gel electro-
phoresis is a specific and robust tool for the screening
of NPM1 mutations and can be performed in less than
2 h. PCR products are run on a ready-to-use 2 %
agarose gel that clearly separates the mutant from the
wild-type band. The remaining PCR product can direct-
ly be sequenced for accurate determination of the type
of mutation. Although the prognostically favorable phe-
notype of NPM1 mutations is independent of the type of
mutation, it is important to identify the precise mutation for
the design of real-time primers and probes for subsequent
monitoring of minimal residual disease by qPCR.
In contrast to other methods, both the specificity and
diagnostic sensitivity of the FAST PCR screening assay
are 100 % (methods reviewed in [12]). The LOD of 5–
10 % mutated alleles equals the sensitivity of other
methods such as capillary electrophoresis and is higher
than for direct sequencing. For minimal residual disease
detection, more sensitive methods such as allele-specific
qPCR are appropriate, yet at the price of a limited
diagnostic sensitivity that is restricted to one specific
mutation per assay.
The FAST PCR technique has the advantage of reducing
time-to-results by approximately a half to two thirds. Many
but not all standard PCR protocols can be converted with
little effort. The protocol presented in this report can also be
run with standard conditions but yields the most PCR prod-
uct by the FAST PCR mode.
We conclude that FAST PCR followed by agarose gel
electrophoresis allows highly specific, rapid and sensi-
tive screening for NPM1 mutations. More precisely, all
mutations were detected and none was missed by this
method. In addition, our assay is inexpensive and can easily be
integrated in the routine molecular diagnostic work-up of
established risk factors in AML using standard laboratory
equipment.
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